

Press release, August 17 2007

FOR MEDIA INFORMATION

Simon Vane Percy / Sarah Roberts
Vane Percy & Roberts
(T) 01737 821891 / 892
(F) 01737 821899
(e) simon@vanepercy.com / sarah@vanepercy.com

Orexo strengthens its clinical and regulatory team with the appointment of three senior executives

Orexo (OMX Midcap:ORX.) has strengthened its clinical and regulatory team with the appointment of three senior executives - Mats Eriksson PhD, VP Research and Clinical Development and Medical Director for Orexo, Christina Ståhl MSc. Pharm, Vice President Regulatory Affairs, and Anne Marie Ciupitu MSc, PhD, Director QA/QC.

Zsolt Lavotha, President and CEO of Orexo AB said, "We are delighted to have been able to attract such experienced people to Orexo. As we are increasing the number of new products in development it is imperative that we ensure that we have the ability to plan the best clinical development and regulatory strategy to be able to bring products to market as quickly as possible."

Mats Eriksson PhD, who is an associate professor of Anaesthesia and Intensive Care at Uppsala University Hospital, has previously worked for Sanofi Synthelabo, Novo Nordisk and, was prior to joining Orexo, Medical Manager of Wyeth Sweden.

Christina Ståhl MSc. Pharm, who is a registered pharmacist, has been working in clinical development and regulatory affairs for the last twenty years with Kabi Vitrum, Pharmacia, Astra Zeneca and was, prior to joining Orexo, Regulatory Affairs Manager/QP for Roche Sweden.

Anne Marie Ciupitu MSc, PhD, has been working as a QA specialist for the last six years with Wyeth Biotech in Sweden. Before joining Orexo she had been appointed Quality Assurance Manager for the company.

For further information contact:

Zsolt Lavotha, President & CEO
Tel: +46 (0)18 780 88 12
Email: zsolt.lavotha@orexo.se

Claes Wenthzel, Executive Vice President & CFO
Tel: +46 (0)18 780 88 44
Email: claes.wenthzel@orexo.se

NOTES TO EDITORS:

About Orexo

Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them. By combining approved active substances with Orexo's drug delivery technologies it is possible to significantly enhance their therapeutic value, such as providing quicker onset of action or ease of administration. This business model is aimed at bringing products to market faster with lower development risk and costs.

Orexo, which has its global headquarters and development laboratories in Sweden, currently operates across the world through development, licensing and distribution agreements in all major markets.

Orexo has a balanced portfolio with two products on the market, three in registration and/or late stage clinical phase and two under formulation development.

Orexo is listed on the OMX Nordic List Mid Cap (ticker;ORX).